[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].
出版信息
Z Kardiol. 1999 Mar;88(3 Suppl):1-4.
PMID:10330699
Abstract
摘要
相似文献
1
[AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering].[AVERT研究（阿托伐他汀与血管重建治疗）。积极降脂的临床优势]
Z Kardiol. 1999 Mar;88(3 Suppl):1-4.
2
Medical therapy versus revascularization: the atorvastatin versus revascularization treatment AVERT trial.
Can J Cardiol. 2000 Jan;16 Suppl A:11A-3A.
3
[Fluvastatin in a comparative study. Are there substance-specific differences between various CSE-inhibitors?].[氟伐他汀的一项比较研究。不同的CSE抑制剂之间是否存在物质特异性差异？]
Internist (Berl). 1999 Mar;40(3 Suppl Gibt Es):1-4.
4
[What is new? Therapy with lipid lowering agents].[有什么新进展？降脂药物治疗]
Internist (Berl). 1997 Nov;38(11 Suppl Therapie):1-8.
5
Atorvastatin--a new lipid-lowering drug.阿托伐他汀——一种新型降脂药物。
Med Lett Drugs Ther. 1997 Mar 28;39(997):29-31.
6
The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.降脂药物降脂以外的有益作用：普伐他汀、阿托伐他汀和非诺贝特治疗IIa型和IIb型高脂血症患者的比较研究
Metabolism. 2005 May;54(5):677-81. doi: 10.1016/j.metabol.2004.12.012.
7
[AVERT [The Atorvastatin versus Revascularization Treatment]].
Nihon Rinsho. 2001 Mar;59 Suppl 3:436-41.
8
Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.在重度高胆固醇血症高危患者中实现脂蛋白目标：依折麦布与阿托伐他汀联合应用的疗效和安全性。
Am Heart J. 2004 Sep;148(3):447-55. doi: 10.1016/j.ahj.2004.03.052.
9
[Prevention of cardiovascular diseases: Value of CSE inhibitors in the management of lipid metabolism disorders].[心血管疾病的预防：CSE抑制剂在脂质代谢紊乱管理中的价值]
Z Kardiol. 1998 Apr;87(4 Suppl Stellenwer):1-4.
10
Coronary revascularization and aggressive lipid lowering.冠状动脉血运重建和强化降脂治疗。
J Invasive Cardiol. 1999 Feb;11(2):87-9.
Zotero 插件